Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ellipticine + Valproic acid neuroblastoma not applicable detail...
Unknown unknown Vorinostat neuroblastoma not applicable detail...
TP53 mutant Nutlin-3 neuroblastoma resistant detail...
TP53 mutant MI-63 neuroblastoma resistant detail...
Unknown unknown BMS-906024 neuroblastoma not applicable detail...
Unknown unknown 131I-MIBG + Vorinostat neuroblastoma not applicable detail...
Unknown unknown BMS-754807 neuroblastoma not applicable detail...
Unknown unknown Doxorubicin + Vorinostat neuroblastoma not applicable detail...
Unknown unknown Cambinol + Doxorubicin neuroblastoma not applicable detail...
ALK R1275Q Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK F1174L TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK F1245C TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK act mut TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma predicted - sensitive detail...
ALK wild-type TP53 H168R Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK mut TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK wild-type TP53 C176F Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK wild-type TP53 P177T Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK wild-type TP53 mutant Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
ALK amp Tp53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma sensitive detail...
ALK wild-type TP53 wild-type Crizotinib + Cyclophosphamide + Topotecan neuroblastoma no benefit detail...
Unknown unknown Cyclophosphamide + Topotecan neuroblastoma not applicable detail...
Unknown unknown GANT61 neuroblastoma not applicable detail...
Unknown unknown Doxorubicin + GANT61 neuroblastoma not applicable detail...
Unknown unknown GANT61 + Vincristine neuroblastoma not applicable detail...
TP53 wild-type GSK2830371 neuroblastoma predicted - sensitive detail...
TP53 mutant GSK2830371 neuroblastoma resistant detail...
TP53 wild-type Carboplatin + GSK2830371 neuroblastoma predicted - sensitive detail...
TP53 wild-type Doxorubicin + GSK2830371 neuroblastoma predicted - sensitive detail...
Unknown unknown Alisertib + Irinotecan + Temozolomide neuroblastoma not applicable detail...
ALK F1174V Brigatinib neuroblastoma sensitive detail...
ALK F1174L Crizotinib neuroblastoma resistant detail...
ALK F1245C Crizotinib neuroblastoma resistant detail...
ALK R1275Q Crizotinib neuroblastoma conflicting detail...
EML4-ALK Crizotinib neuroblastoma resistant detail...
ALK amp Crizotinib neuroblastoma sensitive detail...
ALK F1174L Lorlatinib neuroblastoma conflicting detail...
ALK F1245C Lorlatinib neuroblastoma sensitive detail...
ALK R1275Q Lorlatinib neuroblastoma sensitive detail...
EML4-ALK Lorlatinib neuroblastoma sensitive detail...
ALK amp Lorlatinib neuroblastoma sensitive detail...
ALK wild-type Lorlatinib neuroblastoma resistant detail...
Unknown unknown Dinutuximab neuroblastoma not applicable detail...
Unknown unknown ABT-751 + Fenretinide neuroblastoma not applicable detail...
Unknown unknown Verteporfin neuroblastoma not applicable detail...
ALK positive Entrectinib neuroblastoma sensitive detail...
Unknown unknown Cisplatin + PHA-680632 neuroblastoma not applicable detail...
ALK F1245V Entrectinib neuroblastoma predicted - sensitive detail...
Unknown unknown Go 6983 neuroblastoma not applicable detail...
Unknown unknown GF109203X neuroblastoma not applicable detail...
Unknown unknown Ribociclib neuroblastoma not applicable detail...
ALK D1091N Alectinib neuroblastoma predicted - sensitive detail...
ALK D1091N Alectinib + Doxorubicin neuroblastoma predicted - sensitive detail...
ALK D1091N AZD3463 neuroblastoma sensitive detail...
ALK D1091N AZD3463 + Doxorubicin neuroblastoma sensitive detail...
Unknown unknown Bevacizumab + Irinotecan + Temozolomide neuroblastoma no benefit detail...
Unknown unknown Prexasertib neuroblastoma not applicable detail...
Unknown unknown Doxorubicin + Prexasertib neuroblastoma no benefit detail...
ALK F1174L ALK L1198P Crizotinib neuroblastoma resistant detail...
ALK F1174L ALK G1123S TAE684 neuroblastoma resistant detail...
ALK F1174L ALK L1198P TAE684 neuroblastoma resistant detail...
ALK F1174L ALK G1123D TAE684 neuroblastoma resistant detail...
ALK R1275Q CEP-28122 neuroblastoma sensitive detail...
ALK F1174L CEP-28122 neuroblastoma sensitive detail...
ALK amp CEP-28122 neuroblastoma sensitive detail...
ALK wild-type CEP-28122 neuroblastoma resistant detail...
ALK F1174L AZD3463 neuroblastoma sensitive detail...
NRAS mutant Alpelisib + Binimetinib neuroblastoma sensitive detail...
ALK amp ALK F1174V Ceritinib neuroblastoma sensitive detail...
ALK amp ALK F1174L Ceritinib neuroblastoma sensitive detail...
ALK R1275Q Ceritinib neuroblastoma sensitive detail...
ALK amp ALK F1174V Crizotinib neuroblastoma sensitive detail...
ALK amp ALK F1174L Crizotinib neuroblastoma sensitive detail...
Unknown unknown JSH-150 neuroblastoma not applicable detail...
ATM P960H Olaparib neuroblastoma sensitive detail...
ATM S1455R Olaparib neuroblastoma sensitive detail...
ATM V1841I Olaparib neuroblastoma sensitive detail...
ATM L1874F Olaparib neuroblastoma sensitive detail...
ATM H2038Y Olaparib neuroblastoma sensitive detail...
ATM K2749I Olaparib neuroblastoma sensitive detail...
ATM A59S Olaparib neuroblastoma sensitive detail...
ATM P604S Olaparib neuroblastoma sensitive detail...
ATM V519I Olaparib neuroblastoma sensitive detail...
ATM S824F Olaparib neuroblastoma sensitive detail...
ATM L1956H Olaparib neuroblastoma no benefit detail...
ATM R2691C Olaparib neuroblastoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT00089245 Phase I Omburtamab Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Recruiting
NCT00601003 Phase II Cyclophosphamide + Nifurtimox + Topotecan Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Recruiting
NCT00602667 Phase I Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting
NCT00885326 Phase I Bevacizumab + Cyclophosphamide + Zoledronic acid N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Active, not recruiting
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Completed
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01492673 Phase II Bevacizumab + Cyclophosphamide + Topotecan Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Completed
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed
NCT01526603 Phase I Melphalan Etoposide Filgrastim Tretinoin Carboplatin High Dose Chemotherapy and Autologous Transplant for Neuroblastoma Recruiting
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01601535 Phase Ib/II Alisertib + Irinotecan + Temozolomide Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01747876 Phase I Ribociclib Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma Terminated
NCT01757626 Phase Ib/II Naxitamab + Sargramostim Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Recruiting
NCT01767194 Phase II Dinutuximab Temsirolimus Irinotecan + Temozolomide Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
NCT01822652 Phase I Cyclophosphamide Fludarabine Pembrolizumab 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN Active, not recruiting
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Recruiting
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting
NCT02030964 Phase I Cyclophosphamide + Topotecan Celecoxib N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Active, not recruiting
NCT02035137 131I-MIBG 131I-MIBG + Irinotecan + Vincristine 131I-MIBG + Vorinostat 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat Recruiting
NCT02075177 Phase I Ketoconazole Fenretinide Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma Available
NCT02095132 Phase Ib/II Adavosertib + Irinotecan WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Recruiting
NCT02124772 Phase I Trametinib Dabrafenib + Trametinib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Recruiting
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed
NCT02139397 Phase Ib/II Eflornithine Bortezomib Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Recruiting
NCT02163356 Phase I Vincristine Fenretinide Ketoconazole Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma Unknown status
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-a ATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02298348 Phase I Cyclophosphamide + Sorafenib + Topotecan Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Active, not recruiting
NCT02303028 Phase Ib/II Pazopanib + Topotecan Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Unknown status
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Recruiting
NCT02337309 Phase I SF1126 SF1126 for Patients With Relapsed or Refractory Neuroblastoma Terminated
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Recruiting
NCT02508038 Phase I Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa Recruiting
NCT02559778 Phase I Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Recruiting
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors And Primary Cns Tumors, With or Without Trk, Ros1, or Alk Fusions Recruiting
NCT02650648 Phase I Aldesleukin + Cyclophosphamide + Naxitamab Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Recruiting
NCT02748135 Phase Ib/II TB-403 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Recruiting
NCT02780128 Phase I HDM201 Ceritinib + Ribociclib Trametinib Next Generation Personalized Neuroblastoma Therapy Recruiting
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Recruiting
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed
NCT03033303 Phase II Isotretinoin + Naxitamab + Sargramostim A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Recruiting
NCT03107988 Phase I Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib Study of Lorlatinib (PF-06463922) Recruiting
NCT03126916 Phase III Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Cisplatin Cyclophosphamide Thiotepa Crizotinib Dexrazoxane Carboplatin Aldesleukin Topotecan Dinutuximab Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting
NCT03189706 Phase I Irinotecan + Naxitamab + Sargramostim + Temozolomide Pilot Study of Chemoimmunotherapy for High-Risk Neuroblastoma Recruiting
NCT03209869 Phase I hu14.18-IL2 Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 Recruiting
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213652 Phase II Ensartinib Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213678 Phase II LY3023414 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting
NCT03363373 Phase III Naxitamab + Sargramostim Naxitamab for Neuroblastoma With Osteomedullary Disease Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Recruiting
NCT03526250 Phase II Palbociclib Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Recruiting